Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 73 clinical trials
Featured trial
A Study Evaluating Safety and Tolerability and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

neoplasm (MPN) or chronic myelomonocytic leukemia (CMML).

chronic myelomonocytic leukemia
stem cell transplantation
bone marrow procedure
myelofibrosis
ruxolitinib
  • 49 views
  • 23 Jul, 2022
  • 36 locations
Reduced MBF Regimen for Patients Over 50 Years With Myeloid Malignancies

(100mg/m2) in patients with myeloid malignancies including AML, MDS and CMML over 50 years.

  • 0 views
  • 07 Jul, 2022
  • 1 location
A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)

This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability, efficacy and PK of APG-2575 in combination with Azacitidine in the patients with AML/MPAL or MDS/CMML

  • 0 views
  • 05 Jun, 2022
  • 2 locations
A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

The purpose of this study is to determine the safety, tolerability, maximum tolerated doses (MTDs) and recommended Phase 2 doses (RP2Ds) of JNJ-74856665 as monotherapy and/or in combinations.

chronic myelomonocytic leukemia
venetoclax
azacitidine
cell transplantation
human chorionic gonadotropin
  • 1 views
  • 29 Jul, 2022
  • 20 locations
GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG (GRAPPA)

Post-transplantation cyclophosphamide (PTCY) has become increasingly popular in the haploidentical HCT setting because it overcomes the HLA-mismatch barrier and levels GVHD risk. This advantage may also prove useful in the context of unrelated donor (UD) transplantation. GVHD prophylaxis for matched unrelated donor hematopoietic cell transplantation (alloHCT) in Europe is mainly …

  • 0 views
  • 09 Jun, 2022
  • 7 locations
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent IDH inhibitor, in patients with IDH1 and/or IDH2-mutant advanced hematologic malignancies who have received standard therapy

blast cells
hematologic malignancy
IDH2
  • 0 views
  • 08 Jul, 2022
  • 36 locations
Tagraxofusp (SL-401) in Patients With CMML or MF

This multi-center, multi-arm trial is evaluating the safety and efficacy of tagraxofusp, a CD123-targeted therapy, in patients with either chronic myelomonocytic leukemia (CMML) or myelofibrosis

chronic myelomonocytic leukemia
ejection fraction
platelet count
monocytosis
cmml-2
  • 145 views
  • 10 May, 2022
  • 10 locations
AZD6738 for Patients With Progressive MDS or CMML

This research study is studying a research drug called AZD6738 as a possible treatment for Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia .

  • 0 views
  • 29 Jan, 2021
  • 3 locations
Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations (CONCERTO)

This is an open-label, nonrandomized phase 2 trial to assess the efficacy of cobimetinib in RAS pathway activated CMML. All eligible patients will be treated daily with cobimetinib in 28

  • 0 views
  • 05 Jul, 2022
  • 1 location
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

positive acute myeloid leukemia, chronic myelomonocytic leukemia, or high-risk myelodysplastic syndrome/myeloproliferative neoplasm that has come back (recurrent) or has not responded to treatment

  • 16 views
  • 21 Feb, 2022
  • 1 location